|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.000 - 0.000|
|52 Week Range|
|PE Ratio (TTM)||9.29|
|Forward Dividend & Yield||0.15 (6.20%)|
|1y Target Est||3.39|
March 21 (Reuters) - China Pioneer Pharma Holdings Ltd : * FY REVENUE INCREASED BY 20.3% TO RMB2,153.9 MILLION * FY NET PROFIT INCREASED BY 17.6% TO RMB280.6 MILLION Source text for Eikon: Further ...
Companies with shares trading at a market price below what they are actually worth, such as China Pioneer Pharma Holdings and Easy Repay Finance & Investment, are deemed undervalued. There’sRead More...
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Robust, high-growth companies such as Shanghai Haohai Biological Technology are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk asRead More...
Categories: Yahoo FinanceChina Pioneer Pharma Holdings Ltd. relative valuation is now NEUTRAL. It was previously rated OVERVALUED, and has a fundamental analysis score of 66. Our analysis is based on comparing China Pioneer Pharma Holdings Ltd. with the following peers – Sinopharm Group Co., Ltd. Class H, Livzon Pharmaceutical Group Inc Class H, Tong Ren Tang Technologies ... Read more (Read more...)